医学
诱导化疗
内科学
阿糖胞苷
奥佐美星
累积发病率
中期分析
肿瘤科
化疗
诱导疗法
柔红霉素
临时的
置信区间
外科
入射(几何)
移植
造血细胞
造血干细胞移植
化疗方案
新辅助治疗
随机对照试验
临床试验
总体生存率
护理标准
奥沙利铂
白血病
养生
维持疗法
队列
依托泊苷
作者
Jessica Anne Pollard,Todd A. Alonzo,Robert B. Gerbing,Matthew A. Kutny,Betsy Hirsch,Gordana Raca,Kasey Joanne Leger,Jennifer Jill Wilkes,Reena Pabari,Aman Wadhwa,Zachary T. Graff,Samir B. Kahwash,Karen M. Chisholm,Joseph H. Chewning,John T. Horan,Richard Aplenc,Andrew E. Place,Sarah Kathleen Tasian,Katherine Tarlock,Sarah Menig
摘要
PURPOSE The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562 ) evaluated liposomal daunorubicin and cytarabine (CPX-351) versus standard daunorubicin/cytarabine (DA) induction therapy in children and young adults with newly diagnosed AML. We hypothesized that CPX-351 given during induction 1 and 2 would improve outcomes compared with DA. PATIENTS AND METHODS Patients (21 years and younger) were randomly assigned to two cycles of DA induction (arm A = DA) or CPX-351 (arm B = CPX-351). All patients also received gemtuzumab ozogamicin in induction 1. Postinduction chemotherapy was according to risk assignment made at the end of induction 1 (EOI1). Those with high-risk (HR) AML received consolidation with allogeneic hematopoietic stem-cell transplantation (HSCT), whereas low-risk (LR) patients received chemotherapy alone. Protocol-specified interim analysis monitored efficacy and futility of CPX-351 induction with respect to the primary end point, event-free survival (EFS) from study entry. Disease-free survival (DFS) was calculated to determine the impact of EOI1 risk assignment. RESULTS Seven hundred twenty-one eligible patients with FLT3 wild-type AML were randomly assigned to DA (n = 358) or CPX-351 (n = 363). Interim analysis determined that the futility monitoring rule was crossed because of inferior EFS in the CPX-351 arm and the random assignment was stopped. The two-year EFS from study entry was 62.2% for DA versus 51.2% for CPX-351 ( P = .011). DFS for patients with HR AML was comparable for both arms. However, DFS was significantly lower and cumulative incidence of relapse (CIR) was higher for LR patients assigned to CPX-351 versus DA (2-year DFS from EOI1: DA: 73.8% v CPX-351 57.5% [ P = .001]; 2-year CIR Arm DA: 23.6% v CPX-351: 39.9% [ P = .001]). CONCLUSION CPX-351 was inferior to DA induction in the AAML1831 trial with differential EFS largely driven by events in LR patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI